Resiquimod (R848)

A Toll-like receptor 7/8 agonist [1]. May be used as an immune adjuvant in cancer vaccines [2]. Resiquimod-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release [3]. Topical treatment of wild-type mice induces systemic autoimmune disease which may be used as a model of systemic Lupus erythematosus [4]. Effect on stem cells depends on cell type [5,6].

References:

1) Jurk et al. (2002), Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848;  Nat. Immunol., 3 499

2) Sabado et al. (2015), Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma;  Cancer Immunol. Res., 3 278

3) Ilyinskii et al. (2014), Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release; Vaccine, 32 2882

4) Yokogawa et al. (2014), Epicutaneous application of toll-like receptor 7 agonists leads to systemic autoimmunity in wild-type mice: a new model of systemic Lupus erthematosus.;  Arthritis Rheumatol., 66 694

5) M Sioud & Y Fløisand Eur. J. Immunol. 2007 37:2834

6) A Miyamoto et al. Cytotechnology 2012 64:331